121
In order to corroborate the Hp/HS like structural characteristics of P. pelagicus F5, the ATR-FTIR 122 spectra has been compared with that of Hp. Both P. pelagicus F5 and Hp were shown to share similar 
132
Post acquisition, the ATR-FTIR spectrum of P. 
151
The digest products detected for Hp were in agreement with a typical mammalian Hp 152 disaccharide profile [45] , with 51.5% of the total products attributable to the trisulphated,
153
∆-UA(2S)-GlcNS(6S) and 22.9% to ∆-UA-GlcNS(6S). A minimal proportion of mono or unsulphated 154 disaccharides, accounting for 12.3%, and 4.3% respectively, were also observed for Hp. In
155
comparison, a more disperse sulphation profile was observed for P. pelagicus F5 than Hp (Table 1) 
174
were referenced against the eight common standards present within Hp and HS (light grey, dotted line). 
175

185
which supports the HPLC-based empirical disaccharide analysis ( Figure 4 and Table 1 ). Together,
186
these data establish that the HS of P. pelagicus F5 is considerably more sulfated (Table 1) 
203
In the presence of low concentrations of Hp, an increase in BACE1 activity was observed ( Figure   204 6A-B), with maximal activation occurring at 625 ng.mL -1 (57.5% ± 3.7, n = 3 
210
This indicates that although P. pelagicus F5 exhibits stimulatory activity, it is significantly less than that
211
of Hp. The percent activity level returned to that of the negative control value at concentrations lower 212 than 312.5 ng.mL -1 , indicating that both inhibitory and stimulatory effects are dose dependent. For both
213
Hp and P. pelagicus F5, BACE1 promotion was followed by enzyme inhibition, as previously reported
214
(Figure 6B-C; [49] . The rate of BACE1 activity between 60 -90 minutes was significantly different from 215 controls lacking either Hp (n = 3-6; t(4) = 7, p <0.003), or P. pelagicus F5 (n = 3-6; t(6) = 7, p<0.004) at 216 625 ng.mL -1 , indicating inhibition was not due to substrate limitations. 
241
Spectra were recorded in 50 mM sodium acetate buffer pH 4.0 in all panels.
243
The CD spectra of BACE1 at pH 4.0 has previously been shown to contain a greater proportion 244 of β-sheet and reduced α-helical content, compared to spectra obtained at pH 7.4, indicating that at an 245 acidic pH, where BACE1 is most active, a conformational change can be observed by CD [52] .
246
Consistent with this, the CD spectra of BACE1 in 50 mM sodium acetate buffer pH 4.0 ( Figure 
263
accompanied by a decrease in antiparallel β-sheet of 8 % ( Figure 8D ). This is in contrast to CD studies
264
in the presence of peptide inhibitors, which did not reveal a secondary structural change in BACE1 [52] .
265
The conformational change of BACE1 upon binding to Hp and P. pelagicus F5 was assessed 266 over a range of ratios ( Figure 7D and 8D). At a B:Hp ratio of 2:1 (w/w), a change in the characteristics
267
of the CD spectrum of BACE1 was observed in the far-UV region (λ < 250 nm; Figure 7A ) that was
268
identified as a reduction in α-helix by 6% and an 19% increase in antiparallel β-sheet structures
269
(NRMSD <0.1) [50] . In addition, an increase in positive ellipticity was observed in the near-UV region
270
(250-300 nm; Figure 7B ) following the addition of Hp, which may be attributed to a change in the 
274
The increase in positive ellipticity observed in the CD spectra of BACE1 in the near-UV region at 
287
289
2.4 Heparin and P. pelagicus F5 destabilise the Alzheimer's BACE1.
290
Both Hp and P. pelagicus F5 were shown to induce a conformational change in BACE1, in contrast to 
331
Peaks corresponding to Gal-6S and 6-OH were identified by NMR analysis, with no detectable 
341
The absence of a band migrating in a similar manner to that of CS when P. 
379
showed that the mode of Hp inhibition is non-competitive, and can prevent access of the substrate.
380
At lower GAG concentrations, differences in BACE1 secondary structure were observed 
388
From a mechanistic standpoint, the decrease in the T m s observed using DSF for both the 
401
One of the major obstacles that precludes the use of mammalian Hp compounds as potential
402
BACE1 inhibitors and pharmaceutical candidates in general, is that of the significant anticoagulant 
444
The retentate obtained for F5 was lyophilised and stored at 4°C prior to use.
446
Agarose gel electrophoresis
448
Agarose gel electrophoresis was performed in 0.55% (w/v) agarose gels (8 x 8 cm, 1.5 mm thick) 449 prepared in 1,3-diaminopropane-acetate buffer pH 9.0 (VWR, UK) , 2-7.5 μg of the of P. pelagicus F5
450
or GAG standards were subjected to electrophoresis utilizing a X-Cell SureLock™ Mini-Cell
451
Electrophoresis System (ThermoFisher, UK). Electrophoresis was performed in 0.5 M 
461
Samples (10 mg, lyophilised) were recorded using a Bruker Alpha I spectrometer in the region of 4000
462
to 400 cm -1 , for 32 scans at a resolution of 2 cm -1 (approx 70 seconds acquisition time), 5 times.
463
Spectral acquisition was carried-out using OPUS software (Bruker) with correction to remove the 464 residual spectrum of the sampling environment.
465
Spectral processing and subsequent data analyses were performed using an Asus Vivobook
466
Pro (M580VD-EB76), equipped with an intel core i7-7700HQ. Spectra were smoothed, employing a
467
Savitzky-Golay smoothing algorithm (R studio v1. 
473
The normalised and corrected matrix of intensities was subject to PCA using singular value 474 decomposition in R studio (v1.1.463) with the mean centred, base prcomp function deployed. 
479
Heteronuclear Single-Quantum Correlation (HSQC) 2-dimensional spectra were collected using 480 standard pulse sequences available. Spectra were processed and integrated using TopSpin (Bruker). 
515
The column was washed extensively, with 2 M NaCl and HPLC grade water, prior to use and between
516
runs.
518
4.6 Determination of human BACE1 inhibitory activity using Förster resonance energy transfer.
519
P. pelagicus F5 and Hp were assayed for inhibitory potential against human beta-secretase (BACE1) 520 using the fluorescence resonance energy transfer (FRET) inhibition assay, essentially as described by 
531
The circular dichroism (CD) spectra of native, human BACE1 (6.12 μM, 30 μl; Acro Biosystems, USA) 532 in 50 mM sodium acetate (pH 4.0; VWR, UK) was obtained using a J-1500 Jasco CD spectrometer and
533
Spectral Manager II software, equipped with a 0.2 mm path length quartz cuvette (Hellma, USA)
534
operating at a scan speed of 100 nm.min -1 with 1 nm resolution over the range λ = 190 -320 nm.
535
Spectra obtained were the mean of five independent scans. Human BACE1 was buffer exchanged (in 536 order to remove commercially supplied buffer) prior to spectral analysis using a 10 kDa Vivaspin 537 centrifugal filter (Sartorius, Germany) at 12,000 g washed thrice. Collected data was processed using
538
Spectral Manager II software and data analysis carried out with GraphPad Prism 7, employing a 539 second order polynomial smoothed to 9 neighbours. Secondary structure prediction was performed
540
utilizing the BeStSel analysis server on the unsmoothed data [50] .To ensure the CD spectral change of
541
BACE1 in the presence of each GAG was not altered owing to the addition of the GAG alone, which are known to possess CD spectra at high concentrations [74, 75] , GAG control spectra were subtracted 543 before analysis. In addition, the theoretical, summative CD spectra was confirmed to differ from the 544 observed experimental CD spectra, thereby indicating that the change in the CD spectra compared to 545 that of BACE1 alone is a result of a conformational change upon binding to the GAG. The 546 conformational change observed is believed to occur as a result of changes solely in BACE1 547 secondary structure, as GAG controls exhibited negligible spectra at the concentration used. All CD 548 data have been presented with GAG controls subtracted. 
577
The EC 50 values of all test and control samples were determined using a sigmoidal dose response 
of 28
Supplementary Materials: Figure S1 : The CD structural change of BACE1 observed in the presence of P.
581
pelagicus F5 with a ratio of 2:1 w/w. 582 583
